Experimental medicine: invited stage two application supports academic teams testing disease mechanisms through human interventions to generate insights that could inform future therapies or diagnostics.
Funder: UK Research and Innovation
Due Dates: February 24, 2027, 4:00pm UK time (Closing date) | June 9–10, 2027 (Expected interviews)
Funding Amounts: No funding or duration limit; requests typically £1 million or more; 80% full economic cost
Summary: Supports academically led human interventions that test disease mechanisms and generate insights with a clear path to clinical impact.
Key Information: Stage two applications require an invitation following successful stage one assessment or an invited stage two resubmission.
The Medical Research Council (MRC), part of UK Research and Innovation, funds experimental medicine research into the causes, progression and treatment of human disease. Projects must address a clearly articulated gap in human pathophysiology through an experimental intervention or challenge with an established safety profile. The aim is new mechanistic understanding that could identify opportunities to modify disease pathways or enable future therapeutic or diagnostic approaches.
Research across all human disease areas is eligible, in UK or global health contexts. Challenges may be pharmacological, immunological, physiological, psychological or infectious. Supported approaches include novel readouts used primarily to understand disease mechanisms, and established drugs or interventions used in new settings as investigative tools. Early efficacy signals may be secondary measures, but developing or evaluating new treatments is outside the programme’s remit.